Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer
Japanese Journal of Clinical Oncology · 2024
DOI: 10.1093/jjco/hyae072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2024. Verfasst von Yue Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Peking University First Hospital, Beijing 100034, China. Hauptthemen laut MEDLINE: Class I Phosphatidylinositol 3-Kinases, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
Our aim was to compare the PIK3CA mutation status in matched primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) breast cancer (BC) to gain insight into the optimization of patient selection and detection time for PIK3CA-targeted therapy.
Methods
The data were from 3035 patients with BC diagnosed at the Breast Disease Center, Peking University First Hospital, between January 2008 and December 2017. Matched primary and recurrent samples were profiled using amplification-refractory mutation system-polymerase chain reaction covering 11 mutational hotspots in PIK3CA.
Results
PIK3CA mutations were detected in 54.3% primary tumors and 48.6% corresponding recurrences. PIK3CA mutation was detected in 37.5% cases in the locoregional recurrent group and 40.0% of distant metastasis, without a statistical difference. Besides, PIK3CA mutations were concordant in 88.6% of the matched pairs. For patients treated with neoadjuvant chemotherapy, 100% concordance was observed. However, PIK3CA mutation was neither correlated with clinicopathological features nor associated with clinical outcomes.
Conclusions
Mutations in PIK3CA in HR+/HER2− BC generally progressed to recurrent tumors. The high concordance rate of PIK3CA mutation status between primary tumors and corresponding recurrences suggests that the detection of primary tumors could be a substitute approach when recurrent samples are not easily obtainable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Peking University First Hospital, Beijing 100034, China.
- Breast Disease Center, Peking University First Hospital, Beijing 100034, China.
ORCID-Profile: Yue Wang
Zitieren
APA
Wang, Y., Li, X., Zhang, S., Liang, L., Xu, L., Liu, Y., & Li, T. (2024). Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae072
Vancouver
Wang Y, Li X, Zhang S, Liang L, Xu L, Liu Y, et al. Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer. Japanese Journal of Clinical Oncology. 2024. doi:10.1093/jjco/hyae072
BibTeX
@article{Wang2024,
author = {Wang, Yue and Li, Xin and Zhang, Shuang and Liang, Li and Xu, Ling and Liu, Yinhua and Li, Ting},
title = {Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
doi = {10.1093/jjco/hyae072}
}
EUVIMED